Literature DB >> 10673970

How useful are unconventional cancer treatments?

E Ernst1, B R Cassileth.   

Abstract

Unconventional cancer treatments are used frequently. Therefore, oncologists need to know about them. This article gives an overview of current knowledge on the most prevalent complementary or alternative cancer therapies. A distinction is made between alleged cures, preventive and adjunctive measures. Shark cartilage, mistletoe, thymus therapy, essiac, hydrazine sulphate, 714-X, dietary regimens, green tea and Panax ginseng are all covered specifically. None of these treatments offer reasonable hope for a cure. Some strategies are promising in terms of cancer prevention. The true potential of unconventional therapies might lie in adjunctive and palliative care. It is concluded that good evidence in this area is scarce. Vis-à-vis the high prevalence of unconventional cancer treatments, rigorous investigations are mandatory, not least for increasing the safety of future patients.

Entities:  

Mesh:

Year:  1999        PMID: 10673970     DOI: 10.1016/s0959-8049(99)00198-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Proof versus plausibility: rules of engagement for the struggle to evaluate alternative cancer therapies.

Authors:  L J Hoffer
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

Review 2.  [Chinese medicine as vegetative systems biology. Part I: therapeutic methods].

Authors:  H J Greten
Journal:  HNO       Date:  2011-12       Impact factor: 1.284

3.  Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer.

Authors:  Catalina Lawsin; Katherine DuHamel; Steven H Itzkowitz; Karen Brown; Helen Lim; Linda Thelemaque; Lina Jandorf
Journal:  Support Care Cancer       Date:  2007-01-05       Impact factor: 3.603

4.  Key role of hydrazine to the interaction between oxaloacetic against phosphoenolpyruvic carboxykinase (PEPCK): ONIOM calculations.

Authors:  Pongthep Prajongtat; Darinee Sae-Tang Phromyothin; Supa Hannongbua
Journal:  J Mol Model       Date:  2013-04-27       Impact factor: 1.810

5.  Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Authors:  A Kolstad; T Risberg; Y Bremnes; T Wilsgaard; H Holte; O Klepp; O Mella; E Wist
Journal:  Support Care Cancer       Date:  2004-02-06       Impact factor: 3.603

6.  The association between mental distress and the use of alternative medicine among cancer patients in North Norway.

Authors:  T Risberg; B K Jacobsen
Journal:  Qual Life Res       Date:  2003-08       Impact factor: 4.147

7.  [Secondary prevention after urological cancers. What are the pertinent facts about aftercare?].

Authors:  A Schroeder
Journal:  Urologe A       Date:  2007-06       Impact factor: 0.639

8.  Stakeholders' perspectives on the regulation and integration of complementary and alternative medicine products in Lebanon: a qualitative study.

Authors:  Mohamad Alameddine; Farah Naja; Sarah Abdel-Salam; Salwa Maalouf; Claudia Matta
Journal:  BMC Complement Altern Med       Date:  2011-08-28       Impact factor: 3.659

9.  Potential health risks of complementary alternative medicines in cancer patients.

Authors:  U Werneke; J Earl; C Seydel; O Horn; P Crichton; D Fannon
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation.

Authors:  K Hostanska; V Vuong; S Rocha; M S Soengas; C Glanzmann; R Saller; S Bodis; M Pruschy
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.